|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,202.00 JPY | -3.72% |
|
+1.64% | +5.21% |
| 07-13 | Pfizer, Astellas Secure FDA Nod For Bladder Cancer Drug | MT |
| 07-10 | Health Care Down on Rotation Back to Tech - Health Care Roundup | DJ |
| Market Cap | 4,097B 25.7B 22.32B 20.73B 19.11B 36B 2,453B 36.66B 245B 96.07B 1,218B 96.49B 94.38B | P/E 2027 * |
11.9x | P/E 2028 * | 12.4x |
|---|---|---|---|---|---|
| Enterprise Value | 3,967B 24.88B 21.61B 20.07B 18.51B 34.86B 2,375B 35.49B 238B 93.02B 1,180B 93.43B 91.38B | EV / Sales 2027 * |
1.76x | EV / Sales 2028 * | 1.74x |
| Free-Float |
97.66% | Yield 2027 * |
3.51% | Yield 2028 * | 3.63% |
Last Transcript: Astellas Pharma Inc.
| 1 day | -3.72% | ||
| 1 week | +1.64% | ||
| Current month | +1.24% | ||
| 1 month | +3.89% | ||
| 3 months | -0.23% | ||
| 6 months | +2.39% | ||
| Current year | +5.21% |
| 1 week | 2,166 |  | 2,305.5 |
| 1 month | 2,105 | | 2,305.5 |
| Current year | 2,041 | | 2,717 |
| 1 year | 1,549 | | 2,717 |
| 3 years | 1,243.5 | | 2,717 |
| 5 years | 1,243.5 | | 2,717 |
| 10 years | 1,243.5 | | 2,717 |
| Manager | Title | Age | Since |
|---|---|---|---|
Naoki Okamura
CEO | Chief Executive Officer | 63 | 09/02/2023 |
Kitamura Atsushi
DFI | Director of Finance/CFO | 54 | 31/10/2023 |
Tatjana Dragovic
CMP | Compliance Officer | - | 31/03/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Kenji Yasukawa
CHM | Chairman | 66 | 09/02/2023 |
Naoki Okamura
BRD | Director/Board Member | 63 | 31/05/2019 |
| Director/Board Member | 58 | 31/05/2023 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -3.72% | +1.64% | +39.50% | +5.84% | 25.7B | |
| -4.55% | -2.61% | +51.95% | +151.91% | 1,030B | |
| -3.66% | -1.33% | +52.95% | +46.62% | 617B | |
| -2.24% | +0.19% | +35.97% | +70.64% | 455B | |
| +0.78% | +0.37% | +38.62% | +31.71% | 350B | |
| +0.50% | +0.47% | +35.36% | +40.00% | 299B | |
| +0.21% | +0.65% | +12.61% | +14.00% | 265B | |
| -0.43% | +2.68% | +4.67% | -39.72% | 225B | |
| 0.00% | +4.34% | +28.63% | +64.00% | 209B | |
| -1.09% | +0.32% | +14.40% | +70.80% | 163B | |
| Average | -0.48% | +4.90% | +31.47% | +45.58% | 363.84B | |
| Weighted average by Cap. | +0.05% | +4.88% | +38.57% | +71.52% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 2,260B 14.17B 12.31B 11.43B 10.54B 19.86B 1,353B 20.22B 135B 52.98B 672B 53.21B 52.05B | 2,079B 13.04B 11.33B 10.52B 9.7B 18.27B 1,245B 18.6B 125B 48.75B 618B 48.96B 47.89B |
| Net income | 343B 2.15B 1.87B 1.73B 1.6B 3.01B 205B 3.06B 20.51B 8.03B 102B 8.07B 7.89B | 331B 2.07B 1.8B 1.67B 1.54B 2.91B 198B 2.96B 19.81B 7.76B 98.36B 7.79B 7.62B |
| Net Debt | -130B -816M -709M -658M -607M -1.14B -77.88B -1.16B -7.79B -3.05B -38.68B -3.06B -3B | -472B -2.96B -2.57B -2.39B -2.2B -4.15B -283B -4.23B -28.29B -11.07B -140B -11.12B -10.88B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 31/07/26 | JP¥2,202.00 | -3.72% | 8,229,600 |
| 30/07/26 | JP¥2,287.00 | -0.37% | 8,531,100 |
| 29/07/26 | JP¥2,295.50 | +2.78% | 9,394,300 |
| 28/07/26 | JP¥2,233.50 | +1.06% | 7,062,100 |
| 27/07/26 | JP¥2,210.00 | +2.01% | 5,781,500 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- 4503 Stock
Select your edition
All financial news and data tailored to specific country editions
